H.C. Wainwright analyst Andrew S. Fein lowered the price target on Liquidia Technologies (NASDAQ: LQDA) to $29.00 (from $32.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Liquidia Technologies (LQDA) PT Lowered to $23 at BofA SecuritiesAugust 20, 2024 4:56 AM United Therapeutics Corp. (UTHR) PT Raised to $380 at Wells FargoAugust 20, 2024 4:53 AM Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)August 20, 2024 4:51 AM Liquidia Technologies (LQDA) PT Lowered to $17 at JefferiesAugust 19, 2024 4:01 PM Raymond James Upgrades Liquidia Technologies (LQDA) to Strong BuyAugust 19, 2024 12:01 PM Liquidia Technologies (LQDA) PT Lowered to $25 at BTIGAugust 19, 2024 11:15 AM Midday movers: Estee Lauder, HP Inc fall; AMD risesAugust 19, 2024 7:33 AM Form 8-K Liquidia Corp For: Aug 19August 19, 2024 7:01 AM Liquidia Technologies (LQDA) Granted FDA Tentative Approval for YUTREPIAAugust 19, 2024 6:20 AM U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung August 19, 2024 6:00 AM Liquidia Technologies (LQDA) Announces Poster Presentations at the PHA 2024 InternationalAugust 16, 2024 6:31 AM Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific SessionsAugust 16, 2024 6:30 AM